Like FDA, EMA prioritizes patient safety and data integrity in clinical trials amid outbreak

Days after FDA outlined its thinking on adjustments to planned and ongoing clinical trials during the COVID-19 outbreak, EMA has followed suit with guidance that echoes many of the U.S. regulator's recommendations.

Like FDA's guidance, which was issued Wednesday, the EMA document emphasizes maintaining trial participants' safety and well-being amid anticipated changes to studies, while preserving the trials' integrity as much as possible (see "FDA Stresses Trials' Safety, Integrity During Outbreak")...